Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Innovation, Partnerships, and Leadership: A 2021 Outlook

• So far in 2021, Tryp’s innovations have allowed it to position itself as a first-mover in the psychedelics space
• The company has announced completion of psychotherapy training for the upcoming phase 2a clinical trials for specific overeating disorders
• Tryp has also been keen on collaborating and partnering with key players in the industry, such as Calvert Labs and Gad Consulting services, the University of Michigan, and the University of Florida
• The company also understands the value of proper leadership and, so far in 2021, it has made strategic appointments to its board of directors

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company that has remained focused on developing clinical-stage compounds for diseases with high unmet medical needs. Whereas its focus is on achieving this end through accelerated regulatory pathways, the company also understands the value of innovation, forging the right partnerships, and having exemplary leadership. So far, in 2021, Tryp has made some significant strides from an innovation standpoint, ultimately positioning itself as a first-mover in the psychedelics space.  Its lead drug candidate, TRP-8802, has proven to be promising in treating fibromyalgia (https://ibn.fm/c0oqI). The company believes that… Read More>> NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF About PsychedelicNewsWire PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics. To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.PsychedelicNewsWire.com Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer Do you have questions or are you interested in working with PNW? Ask our Editor PsychedelicNewsWire (PNW) San Francisco, California www.PsychedelicNewsWire.com 415.949.5050 Office [email protected] PsychedelicNewsWire is part of the InvestorBrandNetwork.